JP6147432B2 - Method for producing type II crystals of sarpogrelate hydrochloride - Google Patents
Method for producing type II crystals of sarpogrelate hydrochloride Download PDFInfo
- Publication number
- JP6147432B2 JP6147432B2 JP2016527915A JP2016527915A JP6147432B2 JP 6147432 B2 JP6147432 B2 JP 6147432B2 JP 2016527915 A JP2016527915 A JP 2016527915A JP 2016527915 A JP2016527915 A JP 2016527915A JP 6147432 B2 JP6147432 B2 JP 6147432B2
- Authority
- JP
- Japan
- Prior art keywords
- type
- crystal
- crystals
- sarpogrelate hydrochloride
- acetonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、サルポグレラート塩酸塩のII型結晶の製造方法に関する。 The present invention relates to a method for producing type II crystals of sarpogrelate hydrochloride.
下記一般式(1)で表されるサルポグレラート(Sarpogrelate)塩酸塩は、血小板及び血管のセロトニン受容体(5−HT)を選択的に拮抗する作用機序を持っている。具体的にサルポグレラート塩酸塩は、抗血小板作用及び血管収縮抑制作用を有するため、臨床的に慢性動脈閉塞症による潰瘍、疼痛及び冷感などの虚血性諸症上の抑制及び治療剤として用いられている。 Sarpogrelate hydrochloride represented by the following general formula (1) has an action mechanism that selectively antagonizes platelet and vascular serotonin receptors (5-HT). Specifically, sarpogrelate hydrochloride has an antiplatelet action and a vasoconstriction inhibitory action, so it is clinically used as an agent for inhibiting and treating ischemic diseases such as ulcers, pain and cold feeling due to chronic arterial occlusion. Yes.
サルポグレラート(Sarpogrelate)塩酸塩の製造方法は、特許文献1の実施例2で初めて開示している。前記特許文献1によれば、複数段階の製造過程を経て中間体として2−[2−ヒドロキシ−3−ジメチルアミノプロポキシ]−3’−メトキシビベンジル塩酸塩を製造し、製造された中間体の塩酸塩を中和して塩を除去して2−[2−ヒドロキシ−3−ジメチルアミノプロポキシ]−3’−メトキシビベンジルの形態に転換し、コハク酸無水物と反応させてから塩化水素−エチルアセテート溶液に反応させることで、サルポグレラート塩酸塩を製造した。前記特許文献1では、サルポグレラート塩酸塩の結晶形態に関しては特に言及していない。
特許文献2では、前記特許文献1で製造されたサルポグレラート塩酸塩がI型とII型の2つの結晶が存在するということを明らかにした。また、特許文献1の実施例2で製造されたサルポグレラート塩酸塩は、I型が30モル%で、II型が70モル%の多結晶化合物であると開示している。また、特許文献2には、特許文献1の実施例2で製造されたサルポグレラート塩酸塩(以下、粗結晶)をアセトン、キシレン、水またはアセトンと水の混合溶媒に加温溶解し、25℃に冷却した後、生成された結晶を濾過、洗浄してII型を製造する方法を開示している。しかし、特許文献2に開示された方法で用いられた溶媒は、粗結晶の溶解度が低くて10倍以上の過量を使用しなければならないため、前記方法を工業的に利用するためには大規模な製造設備が必要で、溶媒の廃棄処理が困難である。
特許文献3では、粗結晶を含水アセトンまたは含水メチルエチルケトンに溶解させ、ここに10℃以下に冷却させたアセトンまたはメチルエチルケトンを滴下してII型を70〜90モル%含む結晶混合物を得た。前記特許文献3で提案している結晶化方法によれば、II型結晶の含量をより高め、結晶化溶媒の使用量を減らすという長所はあるが、結晶化溶媒として水を使用するため、サルポグレラートのコハク酸エステルが加水分解され、下記一般式(2)で表される化合物が不純物として生成され、II型結晶の純度及び収率を低下させるという問題がある。
A method for producing sarpogrelate hydrochloride is first disclosed in Example 2 of Patent Document 1. According to Patent Document 1, 2- [2-hydroxy-3-dimethylaminopropoxy] -3′-methoxybibenzyl hydrochloride is produced as an intermediate through a multi-stage production process. The hydrochloride is neutralized to remove the salt and converted to the 2- [2-hydroxy-3-dimethylaminopropoxy] -3′-methoxybibenzyl form, reacted with succinic anhydride, and then hydrogen chloride— Sarpogrelate hydrochloride was prepared by reacting with an ethyl acetate solution. In Patent Document 1, no particular mention is made regarding the crystalline form of sarpogrelate hydrochloride.
Patent Document 2 clarified that the sarpogrelate hydrochloride produced in Patent Document 1 has two crystals of type I and type II. Moreover, it is disclosed that the sarpogrelate hydrochloride produced in Example 2 of Patent Document 1 is a polycrystalline compound having a form I of 30 mol% and a form II of 70 mol%. In Patent Document 2, sarpogrelate hydrochloride (hereinafter referred to as crude crystal) produced in Example 2 of Patent Document 1 is dissolved by heating in acetone, xylene, water or a mixed solvent of acetone and water and heated to 25 ° C. It discloses a method for producing type II by cooling and cooling the produced crystals after cooling. However, since the solvent used in the method disclosed in Patent Document 2 has a low solubility of the crude crystals and must be used in an excess of 10 times or more, it is a large scale in order to use the method industrially. Manufacturing equipment is required, and it is difficult to dispose of the solvent.
In Patent Document 3, crude crystals were dissolved in water-containing acetone or water-containing methyl ethyl ketone, and acetone or methyl ethyl ketone cooled to 10 ° C. or lower was added dropwise to obtain a crystal mixture containing 70 to 90 mol% of type II. According to the crystallization method proposed in Patent Document 3, there is an advantage that the content of type II crystals is further increased and the amount of crystallization solvent used is reduced. However, since water is used as the crystallization solvent, sarpogrelate The succinic acid ester is hydrolyzed and a compound represented by the following general formula (2) is produced as an impurity, which reduces the purity and yield of the type II crystal.
前記一般式(2)で表される化合物は分解産物であって、水やアルコール類を用いて再結晶する場合に生成され、目的とする結晶化合物の純度に非常に大きな影響を及ぼす。
以上、従来技術に示すように、サルポグレラート(Sarpogrelate)塩酸塩の粗結晶からII型結晶をより効率的に得るために、小量の結晶化溶媒を使用し、前記一般式(2)で表される分解産物の生成を招く水またはアルコール類を結晶化溶媒に使用しない、新たな結晶化方法の開発が求められる。
The compound represented by the general formula (2) is a decomposition product, which is produced when recrystallization is performed using water or alcohols, and has a great influence on the purity of the target crystalline compound.
As described above, as shown in the prior art, a small amount of a crystallization solvent is used to obtain a type II crystal from a crude crystal of sarpogrelate hydrochloride, and is represented by the general formula (2). Therefore, it is necessary to develop a new crystallization method that does not use water or alcohols that cause generation of decomposition products as crystallization solvents.
本発明の発明者らはサルポグレラート(Sarpogrelate)塩酸塩の粗結晶から再結晶過程を用いて簡単で経済的な工程から純粋なII型結晶を製造できる方法を研究してきた。その結果、アセトニトリル(AN)がサルポグレラート(Sarpogrelate)塩酸塩に対する溶解度に優れ、再結晶過程で前記一般式(2)で表される分解産物の生成を誘導することなく、未反応の出発物質または他の不純物を容易に除去できるため、粗結晶の再結晶溶媒として効果的であることを見出し、本発明を完成した。
したがって、本発明は、アセトニトリルを再結晶溶媒として用いてサルポグレラート(Sarpogrelate)塩酸塩の粗結晶からII型結晶を高純度に得る方法を提供することを目的とする。
The inventors of the present invention have been investigating a method by which a pure type II crystal can be produced from a crude crystal of Sarpogrelate hydrochloride using a recrystallization process from a simple and economical process. As a result, acetonitrile (AN) has excellent solubility in sarpogrelate hydrochloride, and does not induce the formation of the decomposition product represented by the general formula (2) in the recrystallization process. Thus, the present invention was completed by finding that it is effective as a recrystallization solvent for crude crystals.
Accordingly, an object of the present invention is to provide a method for obtaining type II crystals with high purity from crude crystals of sarpogrelate hydrochloride using acetonitrile as a recrystallization solvent.
本発明は、サルポグレラート塩酸塩の粗結晶をアセトニトリルに加温溶解する過程と、粗結晶の溶液を0〜20℃の温度に冷却して生成された結晶を濾過する過程と、を含むサルポグレラート塩酸塩のII型結晶の製造方法をその特徴とする。
また、本発明は、棒状のサルポグレラート塩酸塩のII型結晶をその特徴とする。
The present invention relates to a sarpogrelate hydrochloride comprising a step of heating and dissolving a crude crystal of sarpogrelate hydrochloride in acetonitrile, and a step of cooling a solution of the crude crystal to a temperature of 0 to 20 ° C. and filtering the produced crystal. The production method of type II crystal is characterized.
Further, the present invention is characterized by a rod-shaped sarpogrelate hydrochloride type II crystal.
本発明による再結晶方法によれば、前記一般式(2)で表される加水分解物が不純物として含まれていることがほとんどないため、II型結晶の収率及び純度を向上させることができる。
本発明による再結晶方法によれば、II型結晶の収率及び純度が高く、工程上の煩わしさがないため、II型結晶の大量生産に効果的である。
本発明による再結晶方法によれば、出発物質の加温溶解及び冷却過程での条件を調節することによって、I型結晶とII型結晶の含量比を容易に調節できるという効果がある。
According to the recrystallization method of the present invention, since the hydrolyzate represented by the general formula (2) is hardly contained as an impurity, the yield and purity of the type II crystal can be improved. .
According to the recrystallization method of the present invention, the yield and purity of type II crystals are high and there is no inconvenience in the process, which is effective for mass production of type II crystals.
According to the recrystallization method of the present invention, there is an effect that the content ratio of the type I crystal and the type II crystal can be easily adjusted by adjusting the conditions in the process of warming dissolution and cooling of the starting material.
本発明で製造するサルポグレラート塩酸塩のII型結晶に対するX線回折分析(XRD)、示差走査熱分析(DSC)、赤外線(IR)分光分析、核磁気共鳴分光分析(NMR)の結果は、特許文献2に開示した分析結果と一致した。
また、特許文献2など従来方法で製造されたII型結晶は、無定形に近い結晶性粉末(powder)として得られた。しかし、本発明による製造方法で製造されたII型結晶は、図1の電子顕微鏡写真から分かるように、棒状の結晶形として得られるが、これはII型結晶の純度がさらに高くなることにその理由があると判断される。
また、本発明による製造方法で製造された棒状のII型結晶は、従来方法で製造された粉末状のII型結晶に比較してより安定性に優れたことを下記の実験例から確認することができる。
したがって、本発明の製造方法は、II型結晶の収率及び純度を高める方法であって、II型結晶の結晶構造が棒状の結晶形であることは、本発明によって初めて明らかにした。
The results of X-ray diffraction analysis (XRD), differential scanning calorimetry (DSC), infrared (IR) spectroscopic analysis, and nuclear magnetic resonance spectroscopic analysis (NMR) for the type II crystal of sarpogrelate hydrochloride produced in the present invention are disclosed in Patent Literature It was in agreement with the analysis result disclosed in 2.
Moreover, the II type crystal manufactured by the conventional methods, such as patent document 2, was obtained as crystalline powder (powder) close to amorphous. However, as can be seen from the electron micrograph of FIG. 1, the type II crystal produced by the production method according to the present invention is obtained as a rod-like crystal form. This is because the purity of the type II crystal is further increased. It is judged that there is a reason.
In addition, it should be confirmed from the following experimental examples that the rod-shaped type II crystal produced by the production method according to the present invention is more stable than the powdery type II crystal produced by the conventional method. Can do.
Therefore, the production method of the present invention is a method for increasing the yield and purity of type II crystals, and for the first time, the present invention revealed that the crystal structure of type II crystals is a rod-like crystal form.
このような本発明のII型結晶の製造方法を過程別に分けて具体的に説明すれば下記の通りである。
先ず、粗結晶をアセトニトリルに加温溶解する。
具体的には、サルポグレラート塩酸塩の粗結晶をアセトニトリルに混合し、30〜80℃の温度に加温して溶解する。この際、アセトニトリルは、粗結晶の重量に対して1:2〜8重量倍の範囲で使用し、より好ましくは3〜5重量倍を使用することができる。II型結晶の含量を高めるためには粗結晶を十分に溶解することが良い。粗結晶を十分に溶解するためには、溶媒の使用量を増加するか、加温温度を上昇させるか、加温状態で攪拌時間を長くするなどの方法がある。本発明者らの実験によれば、溶媒を小量使用して攪拌時間を短く維持すると、II型結晶の含量が減少することを確認した。好ましくは最小量の溶媒を用いて適正温度及び適正攪拌時間加温させることである。攪拌時間は反応容量や反応器の種類によって異なるが、約10時間以内で、好ましくは3〜5時間攪拌する。また、反応中に試料を採取して簡単にIR分析を行って攪拌時間を適切に調節することができる。
また、粗結晶の溶解度を高めるために、アセトニトリル以外にもアセトン、テトラヒドロフラン(THF)、ジメチルホルムアミド(DMF)、ジメチルアセトアミド(DMAc)、及びジメチルスルホキシド(DMSO)から選択された1種以上の極性溶媒をさらに含むこともできる。この際、極性溶媒は、アセトニトリルを基準として1:0.01〜0.5体積倍、より好ましくは0.1〜0.5体積倍の範囲で使用することができる。
The method for producing the type II crystal of the present invention will be described in detail according to the process as follows.
First, the crude crystals are dissolved by heating in acetonitrile.
Specifically, the crude crystals of sarpogrelate hydrochloride are mixed with acetonitrile and heated to a temperature of 30 to 80 ° C. to dissolve. In this case, acetonitrile is used in a range of 1: 2 to 8 times by weight, more preferably 3 to 5 times by weight with respect to the weight of the crude crystals. In order to increase the content of type II crystals, it is preferable to dissolve the crude crystals sufficiently. In order to dissolve the crude crystals sufficiently, there are methods such as increasing the amount of solvent used, increasing the heating temperature, or lengthening the stirring time in the heated state. According to the experiments by the present inventors, it was confirmed that the content of type II crystals decreased when a small amount of solvent was used and the stirring time was kept short. Preferably, the minimum amount of the solvent is used and the mixture is heated at an appropriate temperature and an appropriate stirring time. The stirring time varies depending on the reaction volume and the type of the reactor, but it is within about 10 hours, preferably 3 to 5 hours. In addition, a sample can be taken during the reaction and IR analysis can be easily performed to appropriately adjust the stirring time.
In addition to acetonitrile, one or more polar solvents selected from acetone, tetrahydrofuran (THF), dimethylformamide (DMF), dimethylacetamide (DMAc), and dimethyl sulfoxide (DMSO) are used to increase the solubility of the crude crystals. Can further be included. In this case, the polar solvent can be used in a range of 1: 0.01 to 0.5 volume times, more preferably 0.1 to 0.5 volume times based on acetonitrile.
次に、粗結晶の溶液を冷却し、生成された結晶を濾過してII型結晶を得る。
具体的には、十分に溶解した粗結晶の溶液を0〜20℃の温度に冷却し、冷却して生成された結晶を濾過することで、本発明が目的とするII型結晶を得る。前記冷却温度は、より好ましくは0〜10℃を維持する。冷却状態で放置すると、徐々に結晶が析出されるが、冷却状態での放置時間は1〜5時間程度が適当で、より好ましくは1〜3時間放置する。
Next, the crude crystal solution is cooled, and the produced crystals are filtered to obtain type II crystals.
Specifically, a sufficiently dissolved crude crystal solution is cooled to a temperature of 0 to 20 ° C., and the crystal produced by cooling is filtered to obtain the type II crystal targeted by the present invention. The cooling temperature is more preferably maintained at 0 to 10 ° C. When left standing in the cooled state, crystals are gradually precipitated, but the standing time in the cooled state is suitably about 1 to 5 hours, more preferably 1 to 3 hours.
上述した製造方法により製造されたII型結晶は棒状の結晶形として得られた[図1の電子顕微鏡写真参照]。II型結晶が粉末状ではなく、棒状の結晶形として得られたのは、II型結晶の純度が高いからであると判断される。特に、本発明によれば、サルポグレラート塩酸塩の結晶としてII型結晶/I型結晶のモル比が98%以上のII型結晶を製造することができる。 The type II crystal produced by the production method described above was obtained as a rod-like crystal form [see the electron micrograph of FIG. 1]. The reason why the type II crystal was obtained as a rod-like crystal form instead of a powder is considered to be because the purity of the type II crystal is high. In particular, according to the present invention, a type II crystal having a molar ratio of type II crystal / type I crystal of 98% or more can be produced as a crystal of sarpogrelate hydrochloride.
このような本発明は、下記の実施例及び実験例を挙げてさらに詳細に説明するが、本発明がこれによって限定されることはない。 The present invention will be described in more detail with reference to the following examples and experimental examples, but the present invention is not limited thereto.
[実施例]
実施例1.サルポグレラート塩酸塩のII型結晶の製造
本実施例では、特許文献1の実施例2に開示した製造方法によって粗結晶(I型結晶:II型結晶のモル比=30:70、純度99.3%)を製造した。
粗結晶10gをアセトニトリル100mLに入れて5時間還流攪拌した後、10℃に冷却して2時間放置した。生成された結晶を濾過し、アセトニトリルで洗浄して乾燥することで、II型結晶9.3g(収率93%、HPLC純度99.93%、II型結晶/I型結晶のモル比98%以上)を得た。
前記実施例1で製造されたII型結晶(II型結晶/I型結晶のモル比98%以上)に対する電子顕微鏡写真、赤外線(IR)分光スペクトルとX線回折分析図はそれぞれ図1から3に示す。
また、前記実施例1で原料物質として用いられた粗結晶(I型結晶/II型結晶=3/7モル比)に対する赤外線(IR)分光スペクトルとX線回折分析図はそれぞれ図4から5に示す。
[Example]
Example 1. Production of type II crystals of sarpogrelate hydrochloride In this example, crude crystals (Molar ratio of type I crystals: type II crystals = 30: 70, purity 99.3% by the production method disclosed in Example 2 of Patent Document 1) ) Was manufactured.
10 g of crude crystals were placed in 100 mL of acetonitrile and stirred at reflux for 5 hours, then cooled to 10 ° C. and left for 2 hours. The produced crystals were filtered, washed with acetonitrile and dried to give 9.3 g of type II crystals (yield 93%, HPLC purity 99.93%, type II crystal / type I crystal molar ratio of 98% or more) )
The electron micrograph, infrared (IR) spectroscopic spectrum and X-ray diffraction analysis diagram for the type II crystal prepared in Example 1 (type II crystal / type I crystal molar ratio of 98% or more) are shown in FIGS. Show.
Infrared (IR) spectrum and X-ray diffraction analysis diagrams for the crude crystals (type I crystal / type II crystal = 3/7 molar ratio) used as the raw material in Example 1 are shown in FIGS. Show.
実施例2〜7及び比較例1〜3.サルポグレラート塩酸塩のII型結晶の製造
前記実施例1の方法で粗結晶(I型結晶:II型結晶のモル比=30:70、純度99.3%)を再結晶するが、ただし再結晶条件として溶媒の種類、溶媒の使用量、再結晶温度、再結晶時間を異なるようにした。
Examples 2-7 and Comparative Examples 1-3. Production of type II crystals of sarpogrelate hydrochloride Recrystallization of crude crystals (Molar ratio of type I crystals: type II crystals = 30: 70, purity 99.3%) by the method of Example 1 except that recrystallization conditions The solvent type, the amount of solvent used, the recrystallization temperature, and the recrystallization time were made different.
再結晶条件及び製造された生成物の収率、純度及び結晶形状は下記表1に整理した。 The recrystallization conditions and the yield, purity and crystal shape of the manufactured product are summarized in Table 1 below.
[実験例]
実験例1.サルポグレラート塩酸塩のII型結晶の安定性試験
前記実施例1と比較例1で製造されたII型結晶において、熱と水分に対する安定性を比較するために下記の条件で実験を実施した。その結果は下記表2に示した。
<実験条件>
−保管機器:Constant Temp & Humid Chamber SH−201S(製造会社:ACT)
−保管条件:加速試験−温度40±1℃、相対湿度75%
長期保存試験−温度25±1℃、相対湿度60%
−分析機器:HPLC
−標準液と検液の製造
1)標準液:II型結晶0.4mg/mL濃度(100%)で調製して検量線を作成した。
2)検液:加速及び長期保存試験サンプルを1mg/mL濃度で調製して分析した。
3)残存率の計算:HPLCグラフに示したII型結晶の面積値を標準液と比較して含量を計算した。
[Experimental example]
Experimental Example 1 Test of stability of type II crystals of sarpogrelate hydrochloride In order to compare the stability against heat and moisture in the type II crystals produced in Example 1 and Comparative Example 1, experiments were conducted under the following conditions. The results are shown in Table 2 below.
<Experimental conditions>
-Storage equipment: Constant Temp & Humid Chamber SH-201S (Manufacturer: ACT)
-Storage conditions: accelerated test-temperature 40 ± 1 ° C, relative humidity 75%
Long-term storage test-temperature 25 ± 1 ° C, relative humidity 60%
-Analytical instrument: HPLC
-Manufacture of standard solution and test solution 1) Standard solution: A calibration curve was prepared by preparing a type II crystal at a concentration of 0.4 mg / mL (100%).
2) Test solution: Accelerated and long-term storage test samples were prepared and analyzed at a concentration of 1 mg / mL.
3) Calculation of residual ratio: The content was calculated by comparing the area value of the type II crystal shown in the HPLC graph with the standard solution.
前記表2によれば、本発明によるII型結晶は、棒状の結晶構造を持っており、従来方法により製造された粉末状のII型結晶に比較して長時間保管時に熱と水分に対して安定していることが分かる。 According to Table 2, the type II crystal according to the present invention has a rod-like crystal structure, and is resistant to heat and moisture during storage for a long time compared to the powder type II crystal produced by the conventional method. You can see that it is stable.
Claims (4)
前記溶解された混合物を0〜20℃の温度に冷却して生成された棒状のII型結晶を濾過する過程と、を含んでおり、
前記アセトニトリル含有再結晶溶媒が、アセトン及びテトラヒドロフラン(THF)から選択された1種以上の極性溶媒とアセトニトリルとの混合溶媒である、
サルポグレラート塩酸塩のII型結晶の製造方法。 Mixing the acetonitrile-containing recrystallization solvent and the crude crystals of sarpogrelate hydrochloride in a weight ratio of 5 to 7: 1 , and heating and dissolving the mixture at a temperature of 30 to 80 ° C. for 3 to 10 hours;
A step of filtering the crystalline Form II of the rod-like produced by cooling said dissolved mixture to a temperature of 0 to 20 ° C., and Nde including a
The acetonitrile-containing recrystallization solvent is a mixed solvent of one or more polar solvents selected from acetone and tetrahydrofuran (THF) and acetonitrile.
A process for producing type II crystals of sarpogrelate hydrochloride.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130084677A KR101585189B1 (en) | 2013-07-18 | 2013-07-18 | Production method of saporylate hydrochloride crystal form II |
| KR10-2013-0084677 | 2013-07-18 | ||
| PCT/KR2014/006226 WO2015008973A1 (en) | 2013-07-18 | 2014-07-10 | Method for preparing sarpogrelate hydrochloride crystal form ii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016525126A JP2016525126A (en) | 2016-08-22 |
| JP6147432B2 true JP6147432B2 (en) | 2017-06-14 |
Family
ID=52346374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016527915A Expired - Fee Related JP6147432B2 (en) | 2013-07-18 | 2014-07-10 | Method for producing type II crystals of sarpogrelate hydrochloride |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP6147432B2 (en) |
| KR (1) | KR101585189B1 (en) |
| WO (1) | WO2015008973A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11103499B2 (en) | 2016-08-26 | 2021-08-31 | EXCIVA (UG) (haftungsbeschränkt) | Compositions and methods thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101393178B1 (en) * | 2005-02-22 | 2014-05-08 | 미쓰비시 타나베 파마 코퍼레이션 | (±) 2- (dimethylamino) -1 - {[O- (m-methoxyphenethyl) phenoxy] methyl} ethyl hydrogen succinate hydrochloride |
| JP2007217333A (en) * | 2006-02-16 | 2007-08-30 | Ohara Yakuhin Kogyo Kk | Crystal form of sarpogrelate hydrochloride and method for producing the same |
| JP5090770B2 (en) * | 2007-04-06 | 2012-12-05 | ダイト株式会社 | Industrial production method of sarpogrelate hydrochloride |
| KR100881890B1 (en) * | 2007-05-03 | 2009-02-04 | 주식회사 엔지켐 | Method for preparing safogrelate hydrochloride |
| JP4849374B2 (en) * | 2007-05-18 | 2012-01-11 | 株式会社Dnpファインケミカル福島 | Method for preparing mixed crystals of (±)2-(dimethylamino)-1-{[O-(m-methoxyphenethyl)phenoxy]methyl}ethyl hydrogen succinate hydrochloride (I crystal form and II crystal form) |
| JP2008285445A (en) | 2007-05-18 | 2008-11-27 | Hidekazu Takada | Industrial method for producing sarpogrelate hydrochloride |
| KR100911720B1 (en) * | 2009-04-10 | 2009-08-10 | 주식회사 한서켐 | Method for preparing crystalline hydrochloride safoglylate |
| KR20100118747A (en) * | 2009-04-29 | 2010-11-08 | 제일약품주식회사 | Improved preparation method of sarpogrelate hydrochloride |
| KR101027945B1 (en) * | 2009-05-06 | 2011-04-12 | 주식회사 한서켐 | Method for Recrystallization of Hydrochloric Acid Safoacrylate |
| JP6130701B2 (en) * | 2012-04-01 | 2017-05-17 | エシャシ ファーマ リミテッドEshyasi Pharma Limited | Industrial production method of (2RS) -1-dimethylamino-3- {2- [2- (3-methoxyphenyl) ethyl] phenoxy} propan-2-yl hydrogen succinate hydrochloride |
-
2013
- 2013-07-18 KR KR1020130084677A patent/KR101585189B1/en active Active
-
2014
- 2014-07-10 WO PCT/KR2014/006226 patent/WO2015008973A1/en not_active Ceased
- 2014-07-10 JP JP2016527915A patent/JP6147432B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016525126A (en) | 2016-08-22 |
| KR20150010128A (en) | 2015-01-28 |
| WO2015008973A1 (en) | 2015-01-22 |
| KR101585189B1 (en) | 2016-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2970123B1 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| CN104411700B (en) | Polymorphic forms of 4-[5-(pyridin-4-yl)-1H-1,2,4-triazol-3-yl]pyridine-2-carbonitrile and production method thereof | |
| NO341930B1 (en) | Crystalline forms of 4-methyl-N- [3- (4-methylimidazol-1-yl) -5-trifluoromethylphenyl] -3- (4-pyridin-3-ylpyrimidin-2-ylamino) benzamide | |
| US11739057B2 (en) | Polymorphic forms of Belinostat and processes for preparation thereof | |
| JP2007302658A (en) | POLYMORPHIC FORM AND NEW CRYSTAL FORM AND AMORPHOUS FORM OF IMATINIB MESYLATE, AND METHOD FOR PREPARING FORMalpha | |
| EP2448945B1 (en) | Crystalline forms of prasugrel salts | |
| JPWO2005051925A1 (en) | Crystal of phenylalanine derivative and method for producing the same | |
| CN107635976A (en) | Crystallization of 6-bromo-3-hydroxy-2-pyrazinecarboxamide and its production method | |
| GB2550138B (en) | Process for preparing boscalid | |
| JP6147432B2 (en) | Method for producing type II crystals of sarpogrelate hydrochloride | |
| JP7450842B2 (en) | Salts and polymorphs of phenylpyrimidone compounds and their pharmaceutical compositions and uses | |
| US20140323712A1 (en) | Polymorph of 2-[4-[(methylamino)carbonyl]-1h-pyrazol-1-yl]adenosine | |
| JP4681545B2 (en) | Method for producing crystalline polymorphs of platelet aggregation inhibitors | |
| JP2011068611A (en) | Method for purifying 4-amino-5-chloro-2-ethoxy-n-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide | |
| JP5234856B2 (en) | Crystal of compound having NPYY5 receptor antagonistic action | |
| WO2014020553A1 (en) | Salts of pralatrexate | |
| JP7426832B2 (en) | Iguratimod with a novel crystal structure and its production method | |
| JP6663232B2 (en) | Azilsartan having a novel crystal structure and a method for producing the same | |
| KR100828705B1 (en) | Process for preparing sodium dredron hydrate | |
| WO2015151190A1 (en) | Method for producing irsogladine maleate | |
| HK40003591B (en) | Polymorphic forms of belinostat and processes for preparation thereof | |
| HK1218544B (en) | Salt of omecamtiv mecarbil and process for preparing salt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160308 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160308 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161130 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170306 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170417 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170516 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6147432 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |